

## Press Release

April 8, 2026

Sumitomo Pharma Co., Ltd.

### **Notice Regarding Refinancing of Existing Borrowings through a Bridge Loan**

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President, and CEO: Toru Kimura; Securities Code: 4506, Prime Market of TSE; the “Company”) announced today that the Company has decided to refinance its existing borrowings (hereinafter referred to as the “Refinancing”) through a bridge loan (hereinafter referred to as the “Bridge Loan”), as outlined below.

#### 1. Purpose of the Refinancing

As announced in the “Notice Regarding Refinancing of Existing Borrowings Through a Syndicated Loan” dated March 26, 2025, the Company has entered into a syndicated loan agreement for the purpose of refinancing the bridge loan for the acquisition of Myovant Sciences Ltd. as a wholly owned subsidiary and existing borrowings for the strategic alliance with Roivant Sciences Ltd. implemented in December 2019.

In connection with the issuance of new shares and the secondary offering of its shares, as announced on April 8, 2026, the Company has decided to fully repay the existing borrowings guaranteed by Sumitomo Chemical Co., Ltd. and to refinance them through the Bridge Loan without a guarantee from Sumitomo Chemical Co., Ltd.

#### 2. Overview of the Bridge Loan

	Term Loan	Commitment Line
Contract Amount	Total: 20.0 billion JPY	Total: 130.0 billion JPY
Use of Funds	Refinancing of existing borrowings	Working capital
Loan/Commitment Period	April 24, 2026 – April 23, 2027	
Repayment Method	Lump sum repayment on due date	
Presence of Collateral	None	
Joint Guarantor	None	
Lenders	Sumitomo Mitsui Banking Corporation and others	

Note: This press release is a general release regarding a refinancing of existing borrowings through a bridge loan of the Company, and is not prepared for the purpose of investment solicitation or the like in Japan or elsewhere. This press release does not constitute an offer to sell or solicitation of any offer to buy securities in the United States. The shares of common stock of the Company have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “Securities Act”). The shares of common stock of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act. No public offering of the shares of common stock of the Company will take place in the United States.

### 3. Overview of the Existing Syndicated Loan to Be Repaid

	Term Loan (Tranche A)	Commitment Line (Tranche B)
Initial Facility Amount	140.0 billion JPY	93.0 billion JPY
Outstanding Principal Balance (as of April 8, 2026)	60.0 billion JPY	38.1 billion JPY
Use of Funds	Refinancing of existing borrowings	Working capital
Loan/Commitment Period	March 31, 2025 – March 31, 2028	
Repayment Method	Lump sum repayment on due date	
Presence of Collateral	None	
Joint Guarantor	Sumitomo Chemical Co., Ltd.	
Arranger & Agent	Sumitomo Mitsui Banking Corporation	
Co-Arranger	Sumitomo Mitsui Trust Bank, Limited	
Participating Financial Institutions	Sumitomo Mitsui Banking Corporation Sumitomo Mitsui Trust Bank, Limited The Norinchukin Bank Mizuho Bank, Ltd. MUFG Bank, Ltd. The Hyakujushi Bank, Ltd. Aozora Bank, Ltd. The Iyo Bank, Ltd. San ju San Bank, Ltd. The Shiga Bank, Ltd. The Joyo Bank, Ltd. The Hiroshima Bank, Ltd. The Oita Bank, Ltd. The Chiba Bank, Ltd. The Nanto Bank, Ltd. The Kiyo Bank, Ltd.	

### 4. Future Outlook

The impact of the Refinancing on the Company's consolidated financial results for the fiscal year ending March 2027 is expected to be minimal.

Note: This press release is a general release regarding a refinancing of existing borrowings through a bridge loan of the Company, and is not prepared for the purpose of investment solicitation or the like in Japan or elsewhere. This press release does not constitute an offer to sell or solicitation of any offer to buy securities in the United States. The shares of common stock of the Company have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"). The shares of common stock of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act. No public offering of the shares of common stock of the Company will take place in the United States.

#### Disclaimer Regarding Forward-looking Statements

The statements made in this press release contain forward-looking statements based on management's assumptions and beliefs in light of information available as of the day of this release, which involve both known and unknown risks and uncertainties. Actual results of those matters covered in the forward-looking statements including financial forecast may differ materially from those contained in this release, due to a number of factors.

#### Contact:

Corporate Communications,

Sumitomo Pharma Co., Ltd.

E-mail: [prir@sumitomo-pharma.co.jp](mailto:prir@sumitomo-pharma.co.jp)

Note: This press release is a general release regarding a refinancing of existing borrowings through a bridge loan of the Company, and is not prepared for the purpose of investment solicitation or the like in Japan or elsewhere. This press release does not constitute an offer to sell or solicitation of any offer to buy securities in the United States. The shares of common stock of the Company have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"). The shares of common stock of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act. No public offering of the shares of common stock of the Company will take place in the United States.